Onchocerciasis in Sierra Leone 3: Relationships between eye lesions and microfilarial prevalence and intensity

Treatment of onchocerciasis with ivermectin in Sierra Leone

Ivermectin chemotherapy is proving to be a major advance in the management of onchocerciasis. In this article, James Whitworth reviews the work done on onchocerciasis and ivermectin in Sierra Leone and examines the evidence that mass treatment might control the clinical features of the disease and its transmission in West Africa. Ivermectin is safe and effectively reduces microfilarial (mf) loads, with major improvement in some ocular manifestations o f disease. This alone makes mass distribution to communities at risk of blindness worthwhile, even though the impact on other clinical features is less clear cut. Repeated doses have a cumulative effect on adult worms, which may cause more reduction in transmission than hitherto thought likely.

Effects of repeated doses of ivermectin on ocular onchocerciasis: community-based trial in Sierra Leone

Ivermectin seems to be a safe and effective treatment for onchocerciasis when given in a single dose, but less is known about the effects of repeated doses. Also, there seem to be differences in its effectiveness in anterior and posterior segment ocular disease. The ocular effects of ivermectin were studied in 586 villagers who were taking part in a double-blind, placebo-controlled, randomised trial in Sierra Leone. Only those who had received four doses, with 6-month intervals, of ivermectin or placebo were eligible. The 296 ivermectin-treated subjects and the 272 who received placebo were comparable with respect to age, sex, Onchocerca infection, blindness, and visual impairment before treatment. After treatment, the ivermectin group had less anterior segment disease than the placebo group, with significantly lower prevalences of microfilariae in the anterior chamber and cornea, and punctate keratitis (all p less than 0.001), and iritis (p less than 0.05). There was no significant difference in the prevalence of sclerosing keratitis, optic atrophy, or chorioretinitis between the groups. Visual acuities tended to be better in the ivermectin group, but the difference was not significant. There was a small but significant (p less than 0.01) excess of vascular sheathing in the ivermectin group. These differences persisted when subjects who were blind or visually impaired at baseline were excluded from analysis. The long-term effects of ivermectin, particularly on posterior segment disease, need further evaluation. In the mean time, the mass distribution of ivermectin should be promoted for all communities with hyperendemic onchocerciasis at risk of anterior segment disease.

A community trial of ivermectin for onchocerciasis in Sierra Leone: clinical and parasitological responses to the initial dose

A double-blind placebo-controlled trial of ivermectin was started in 1987 in 6 villages in southern Sierra Leone. 1625 villagers, 93% of the total population, were surveyed before treatment and allocated at random to the trial. Onchocerciasis was hyperendemic and of moderate intensity in the area. Typical onchocerciasis skin lesions were seen in most cases; the blindness rate was 1.5% and a further 4.3% had visual impairment. Six months after treatment 988 subjects (80%) were reassessed and microfilarial loads in the ivermectin group were found to be 10% of control levels. Additionally, blood eosinophil concentrations were reduced by one-quarter. The severity, but not the prevalence, of skin lesions was significantly reduced in the ivermectin group, with a particularly marked effect on papular eruptions. There had been no reduction in the prevalence of itching, nor had markers of general health shown improvement after ivermectin. Ivermectin is an effective microfilaricidal agent and may improve Onchocerca-related skin lesions after a single dose. However, the lack of obvious benefit to a target population after the first dose of ivermectin may reduce compliance with subsequent doses. This has implications for planned mass treatment initiatives in onchocerciasis endemic regions.

Onchocerciasis in Sierra Leone.2: A comparison of forest and savanna villages

Very little of the original primary forest remains in Sierra Leone and the savanna is mainly woodland or a forest-savanna mosaic. The prevalence of microfilariae of Onchocerca volvulus, nodules and moderate or severe skin lesions was higher in forest than savanna villages. In forest villages the prevalence of microfilariae was 71.8% at the iliac crest, 36.6% (outer canthus), 12.8% (cornea) and 34.1% in the anterior chamber of the eye. Corresponding figures for the savanna villages were 51.9%, 20.5%, 5.6% and 21.8%. The overall prevalence of nodules in the forest and savanna was 70.5% and 53.2% respectively, while the prevalence of head and upper body nodules was 14.8% (forest) and 11.0% (savanna). The prevalence of moderate or severe skin lesions was 17.7% in forest and 13.0% in savanna villages. Lesions of the groin and scrotum were few in both zones. In persons aged 30 years or more the prevalence rates of severe eye lesions--sclerosing keratitis, iritis, optic atrophy and choroidoretinitis--were 4.3%, 16.1%, 13.9% and 14.8% respectively in forest villages. Corresponding figures for the savanna villages were 3.7%, 8.7%, 14.2% and 11.3%. Males were more commonly affected than females. At least one of these lesions was found in 32% persons in forest and 24% in savanna villages.